Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial.

ABSTRACT:

Background

Accumulating evidence highlights the critical role of circadian rhythms in regulating bone turnover. Bone turnover markers, including parathyroid hormone, C-terminal telopeptide of type I collagen, and N-terminal propeptide of type I procollagen, all exhibit distinct diurnal variations. Teriparatide, a recombinant parathyroid hormone analog, demonstrates time-dependent efficacy influenced by these endogenous rhythms. However, the impact of administration timing on bone metabolism remains underexplored.

Objective

This randomized, open-label, exploratory trial investigates the impact of teriparatide administration timing by comparing subcutaneous injection at 08:00 versus 20:00 on bone turnover markers in postmenopausal women with osteoporosis.

Methods

Twenty

SUBMITTER: Wang H 

PROVIDER: S-EPMC12273002 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature